Transforming Oncology: Emerging Therapies, Technological Innovations, and Patient-Centered Care

Table of Contents

Toggle

10 Key Takeaways from “Transforming Oncology: Emerging Therapies, Technological Innovations, and Patient-Centered Care”:

1. Revolutionary Advances: The field of oncology is experiencing rapid transformation, with significant advances in science and technology driving the development of more individualized and effective cancer treatments.
2. Immunotherapy Breakthroughs: Immunotherapy, particularly through checkpoint inhibitors and CAR-T cell therapy, is offering new hope by enabling the immune system to target and destroy cancer cells more effectively.
3. Targeted Therapy: Targeted therapies, including small molecule inhibitors and monoclonal antibodies, are revolutionizing cancer treatment by focusing on the molecular drivers of cancer with minimal damage to healthy cells.
4. Personalized Medicine: Advances in genomic profiling and biomarker-driven therapies are paving the way for personalized cancer treatment, tailored to the unique genetic makeup of each patient’s tumor.
5. Technological Integration: The integration of AI, machine learning, and next-generation sequencing in oncology is enhancing diagnostics, treatment planning, and drug discovery, leading to more precise and effective care.
6. Combination Therapies: Combining different treatment modalities, such as immunotherapy with chemotherapy or targeted therapy, is becoming the standard in oncology, improving outcomes by attacking cancer from multiple angles.
7. Patient-Centered Care: There is a growing emphasis on patient-centered care, where patients are empowered with information and support to actively participate in their treatment decisions, improving both outcomes and quality of life.
8. Access and Equity Challenges: Despite advancements, access to cutting-edge treatments remains uneven, particularly in low-income regions, underscoring the need for global health initiatives to ensure equitable cancer care.
9. Cost and Affordability: The high cost of new cancer therapies is a significant challenge, raising concerns about financial toxicity for patients and the sustainability of healthcare systems.
10. Ethical Considerations: The rapid pace of innovation in oncology introduces complex ethical dilemmas, including issues of genetic data privacy and the equitable distribution of advanced treatments, necessitating robust ethical guidelines.

---

Please look at the Market Access & HEOR Resource category for more articles.

Subscribe to our newsletter

Thank you for Signing Up

Please correct the marked field(s) below.

1,true,6,Kişi E-postası,2

Introduction

The field of oncology treatment is changing quickly due to significant advances in science and technology. There has never been a more pressing need to create more individualized and efficient cancer treatments because the disease is still one of the top causes of mortality worldwide. The field is currently undergoing a revolutionary change toward more individualized treatments that are both more focused and sensitive to the particular demands of each patient. These developments, which include the emergence of immunotherapy and the use of AI in diagnostics, are changing the way we treat cancer. This article aims to examine the most recent advancements in oncology treatment, highlighting their positive effects on patient outcomes and quality of life. Whether you’re a healthcare professional, a patient, or simply interested in the future of cancer care, understanding these trends is crucial as they redefine the fight against cancer.

Emerging Therapies in Oncology

The field of oncology is undergoing a revolutionary transformation with the development of new therapies that are not only more effective but also more tailored to individual patients’ needs.

Here are some of the most promising emerging therapies in cancer treatment:

Immunotherapy

Immunotherapy has quickly become one of the most exciting areas in oncology, offering new hope for patients with cancers that were once considered untreatable. This approach leverages the body’s immune system to recognize and attack cancer cells, providing a powerful alternative to traditional treatments like chemotherapy and radiation.

Checkpoint Inhibitors: These drugs work by blocking proteins that prevent immune cells from attacking cancer cells. By inhibiting these “checkpoints,” drugs like pembrolizumab and nivolumab have shown remarkable success in treating various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma.

CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy involves genetically modifying a patient’s T cells to express receptors specific to cancer cells. Once reintroduced into the patient’s body, these engineered T cells target and destroy the cancer. CAR-T therapies like axicabtagene ciloleucel and tisagenlecleucel have shown impressive results in treating certain blood cancers, including acute lymphoblastic leukemia (ALL) and large B-cell lymphoma.

Cancer Vaccines: Unlike traditional vaccines, cancer vaccines are designed to stimulate the immune system to attack existing cancer cells. While still in the experimental stages, several cancer vaccines are showing promise, particularly in cancers like prostate and cervical cancer.

Targeted Therapy

Targeted therapies have revolutionized cancer treatment by specifically targeting the molecular changes that drive cancer growth. Unlike chemotherapy, which affects both cancerous and healthy cells, targeted therapies aim to block the growth and spread of cancer cells with minimal damage to normal cells.

Small Molecule Inhibitors: These drugs target specific enzymes, proteins, or other molecules involved in the growth and survival of cancer cells. For example, tyrosine kinase inhibitors (TKIs) like imatinib (used in chronic myeloid leukemia) and gefitinib (used in non-small cell lung cancer) have become standard treatments for cancers with specific genetic mutations.

Monoclonal Antibodies: These laboratory-made molecules can bind to specific targets on cancer cells. For instance, trastuzumab is a monoclonal antibody that targets the HER2 protein, which is overexpressed in some breast cancers. This approach has significantly improved outcomes for patients with HER2-positive breast cancer.

Antibody-Drug Conjugates (ADCs): ADCs combine the targeting ability of monoclonal antibodies with the cancer-killing power of chemotherapy. These therapies deliver cytotoxic agents directly to cancer cells, reducing side effects on healthy tissue. An example is ado-trastuzumab emtansine, used in HER2-positive breast cancer.

Personalized Medicine

Personalized medicine, also known as precision medicine, is an approach that tailors treatment to the individual characteristics of each patient’s cancer. This approach considers genetic, environmental, and lifestyle factors to create a customized treatment plan.

Genomic Profiling: Advances in genomic sequencing have allowed for the identification of specific mutations within a tumor, enabling oncologists to select therapies that are most likely to be effective. For instance, patients with non-small cell lung cancer may undergo testing for EGFR mutations to determine if they are candidates for EGFR inhibitors like osimertinib.

Biomarker-Driven Therapies: The identification of biomarkers—molecules that indicate the presence of cancer—has led to the development of therapies that target these specific markers. For example, the presence of the BRCA mutation in breast or ovarian cancer patients can guide the use of PARP inhibitors like olaparib, which are particularly effective in patients with this genetic profile.

Liquid Biopsies: A non-invasive method to detect cancer-related mutations and monitor treatment response through a simple blood test. This technology is still emerging but holds great potential for real-time tracking of how cancer evolves and responds to treatment.

Combination Therapies

The complexity of cancer often requires a multi-faceted approach. Combination therapies, which involve the use of two or more treatment modalities, are increasingly becoming the standard of care in oncology.

Immunotherapy and Chemotherapy: Combining immunotherapy with traditional chemotherapy has shown improved outcomes in cancers like lung and bladder cancer. This approach can enhance the immune response while directly attacking cancer cells.

Targeted Therapy and Immunotherapy: Another promising combination involves the use of targeted therapies to disrupt cancer cell signaling pathways, alongside immunotherapy to enhance the body’s immune response. For instance, combining BRAF inhibitors with MEK inhibitors and immunotherapy has shown efficacy in treating BRAF-mutated melanoma.

Radiation and Immunotherapy: Radiation therapy is known to kill cancer cells and modulate the tumor environment, making it more susceptible to immune attack. When combined with immunotherapy, radiation can act as an immune adjuvant, increasing the effectiveness of the immune response against cancer.

Technological Innovations in Oncology

The integration of advanced technology in oncology is revolutionizing cancer care, from early detection to personalized treatment plans. These innovations are not only improving patient outcomes but also making cancer treatment more precise and accessible. Below are some of the key technological advancements driving this transformation:

Artificial Intelligence and Machine Learning

Artificial Intelligence (AI) and Machine Learning (ML) are playing increasingly pivotal roles in oncology, offering new capabilities for diagnosis, treatment planning, and drug discovery.

AI in Diagnostics: AI algorithms are now being used to analyze medical images, such as MRIs, CT scans, and mammograms, with remarkable accuracy. These tools can detect tumors at early stages, often with greater precision than human radiologists, which can lead to earlier and more effective treatment.

Predictive Analytics: Machine learning models can predict how patients might respond to certain therapies based on their genetic profiles, previous treatments, and other factors. This helps in crafting personalized treatment plans that are more likely to succeed.

Drug Discovery and Development: AI is accelerating the drug discovery process by identifying potential drug candidates, predicting their effectiveness, and optimizing clinical trial designs. This reduces the time and cost associated with bringing new cancer therapies to market.

Telemedicine and Remote Monitoring

The COVID-19 pandemic accelerated the adoption of telemedicine, and in oncology, this has proven to be particularly beneficial for patient care.

Virtual Consultations: Telemedicine enables oncologists to consult with patients remotely, making it easier for patients to receive care without the need for frequent hospital visits. This is especially useful for those in rural areas or with mobility issues.

Remote Monitoring Devices: Wearable devices and mobile apps now allow for continuous monitoring of patient’s vital signs, treatment adherence, and side effects. These tools can alert healthcare providers to potential issues in real time, enabling timely interventions and reducing the need for hospitalizations.

Home-Based Treatments: Some aspects of cancer treatment, such as chemotherapy, can now be administered at home under remote supervision, thanks to advancements in telemedicine and remote monitoring technologies. This improves patient comfort and reduces the burden on healthcare facilities.

Genomics and Next-Generation Sequencing

Genomic technologies are central to the shift towards personalized medicine in oncology, enabling more precise treatment options based on the genetic makeup of a patient’s tumor.

Next-Generation Sequencing (NGS): NGS allows for comprehensive profiling of a tumor’s genetic mutations, which can guide the selection of targeted therapies. This technology has made it possible to identify actionable mutations in a growing number of cancers, leading to more effective treatments.

Circulating Tumor DNA (ctDNA) Analysis: Liquid biopsies that analyze ctDNA in the blood offer a non-invasive way to monitor tumor mutations over time. This technology helps in detecting residual disease, monitoring treatment response, and identifying resistance mutations, allowing for timely adjustments to therapy.

CRISPR and Gene Editing: CRISPR technology is being explored for its potential to directly edit cancer-related genes, either to knock out oncogenes or to repair defective tumor suppressor genes. While still in the experimental stages, gene editing could become a powerful tool in cancer treatment.

Robotics and Precision Surgery

Advancements in robotics and imaging have made surgical interventions for cancer more precise and less invasive.

Robotic Surgery: Robotic-assisted surgery allows for greater precision, smaller incisions, and quicker recovery times. In oncology, robotic systems are used in procedures like prostatectomies and hysterectomies, where precision is critical.

Image-Guided Surgery: Technologies like intraoperative MRI and fluorescence-guided surgery help surgeons to see tumors more clearly during operations, ensuring more complete removal of cancerous tissue while sparing healthy tissue.

Minimally Invasive Techniques: Innovations in laparoscopic and endoscopic tools are enabling surgeons to perform complex cancer surgeries with minimal invasiveness, reducing recovery times and improving patient outcomes.

Data Integration and Electronic Health Records (EHR)

The management and analysis of vast amounts of patient data is becoming increasingly important in oncology.

Interoperable EHR Systems: Electronic Health Records that can seamlessly share patient data between different healthcare providers ensure that all involved in a patient’s care have access to the same information, facilitating coordinated treatment plans.

Big Data and Cancer Registries: Large datasets from cancer registries and EHRs are being analyzed to uncover trends, identify risk factors, and improve treatment protocols. This data-driven approach is helping to refine cancer care at both individual and population levels.

Patient Portals: Patient-facing platforms are empowering individuals to access their health records, communicate with their healthcare providers, and actively participate in their treatment plans. This increases patient engagement and adherence to therapies.

Patient-Centered Care in Oncology

The landscape of oncology has evolved significantly, with a growing emphasis on patient-centered care, patient empowerment, and the holistic management of cancer. This shift is driven by the recognition that patients are not just passive recipients of care but active participants in their treatment journeys. As a result, there is a concerted effort to provide patients with the information, support, and tools they need to make informed decisions about their care.

Alongside this, the focus has expanded to encompass not only the extension of life but also the enhancement of quality of life, ensuring that patients receive comprehensive care that addresses their physical, emotional, and psychological needs. However, as the field advances, challenges such as access to care, the affordability of new therapies, and ethical considerations around emerging technologies remain critical issues that must be addressed to ensure equitable and ethical cancer care for all patients.

Patient Empowerment and Education

In recent years, there has been a significant shift towards patient-centered care in oncology, where patients are increasingly empowered to take an active role in their treatment decisions. This empowerment stems largely from the availability of accessible and reliable information online, enabling patients to research their diagnoses, treatment options, and potential outcomes. Healthcare providers are also recognizing the importance of educating patients about their conditions and involving them in the decision-making process. Tools such as patient portals, educational webinars, and personalized treatment plans are now commonly used to ensure that patients are well-informed. By understanding their treatment options and the potential risks and benefits, patients can make more informed decisions that align with their personal values and preferences.

Quality of Life and Supportive Care

The focus in oncology is no longer just on extending life but also on enhancing the quality of life for cancer patients. This approach recognizes that managing the side effects of treatment, controlling pain, and providing mental health support are crucial aspects of comprehensive cancer care. Supportive care, which includes palliative care, aims to alleviate the physical, emotional, and psychological burdens of cancer. Innovations in pain management, the integration of mental health services, and the availability of holistic care options such as nutrition counseling and physical therapy are improving the overall well-being of patients. Moreover, palliative care is now being introduced earlier in the treatment process, not just at the end stages, to help patients manage symptoms and maintain a better quality of life throughout their cancer journey.

Patient Advocacy and Involvement

Patient advocacy groups have become powerful forces in shaping cancer care, research, and policy. These organizations provide a voice for patients, helping to influence research priorities, secure funding for new treatments, and ensure that patient needs are addressed in policy-making. Advocacy groups often engage in public awareness campaigns, lobbying efforts, and fundraising activities that drive advances in oncology. Additionally, these groups offer support networks for patients and their families, providing resources and guidance throughout the treatment process. The involvement of patients in clinical trials and research design is also increasing, ensuring that studies are more aligned with patient needs and preferences. This collaboration between patients, advocacy groups, and the medical community is fostering a more inclusive and responsive approach to cancer care.

Challenges and Ethical Considerations

As oncology continues to advance, the field faces significant challenges and ethical considerations that impact patient care. One of the most pressing issues is the disparity in access to cutting-edge treatments, particularly in low-income regions and among marginalized populations. Geographic, socioeconomic, and systemic barriers often prevent equitable access to the latest cancer therapies, highlighting the urgent need for global health initiatives and policy reforms.

Alongside access, the escalating cost of new cancer treatments presents another major challenge, as the financial burden on patients and healthcare systems grows. High costs can limit access to life-saving therapies, raising questions about the sustainability of current pricing models and the need for more equitable approaches, such as value-based pricing.

Additionally, the rapid pace of innovation in oncology introduces complex ethical dilemmas, from the use of genetic data in treatment planning to the implications of emerging technologies like CRISPR. These advancements necessitate careful consideration of patient rights, consent, and privacy to ensure that innovation does not come at the expense of ethical standards in cancer care.

Access and Equity

Despite advancements in oncology, access to cutting-edge treatments remains uneven, particularly in low-income regions and among marginalized populations. Geographic, socioeconomic, and systemic barriers often prevent patients from receiving the latest therapies. In many low- and middle-income countries, limited healthcare infrastructure and financial resources mean that patients do not have access to advanced diagnostics, targeted therapies, or clinical trials. This disparity underscores the need for global health initiatives and policy reforms aimed at improving access to care. Efforts to increase the availability of generic drugs, reduce costs, and expand healthcare coverage are essential to ensure that all patients, regardless of location or income, can benefit from the latest oncology treatments.

Cost and Affordability

The cost of new cancer therapies can be prohibitively high, creating a significant financial burden for patients and healthcare systems. Drugs like immunotherapies and targeted therapies often come with price tags that are out of reach for many, even in high-income countries. The financial toxicity associated with cancer treatment can lead to difficult choices between continuing treatment and managing everyday expenses. Insurance coverage is not always comprehensive, and out-of-pocket costs can be substantial. This issue raises important questions about the sustainability of healthcare systems and the need for pricing reforms, such as value-based pricing, which aligns the cost of a drug with its effectiveness and impact on patient outcomes. Addressing these challenges is crucial to making advanced cancer treatments more affordable and accessible.

Ethical Dilemmas

The rapid pace of innovation in oncology brings with it a host of ethical dilemmas. The use of genetic data in treatment planning, for instance, raises concerns about privacy and the potential for discrimination based on genetic information. Patient consent is another critical issue, particularly in the context of emerging technologies like CRISPR, where the long-term effects and ethical implications are still not fully understood. The expansion of personalized medicine also raises questions about who should have access to these therapies and how to ensure that decisions are made in the best interest of the patient. As these technologies become more widespread, it is essential to establish ethical guidelines that protect patients’ rights while fostering innovation.

Future Directions in Oncology Treatment

The future of oncology treatment is being shaped by groundbreaking research and development, regulatory innovation, and global collaboration. Experimental therapies such as oncolytic viruses, gene therapies, and novel immunotherapies are in clinical trials and show great potential for improving cancer outcomes by targeting the tumor microenvironment and disrupting cancer-supporting conditions within the body.

Regulatory bodies are adapting to these rapid advancements with accelerated approval processes, like the FDA’s Breakthrough Therapy designation, ensuring that promising treatments reach patients faster while emphasizing the need for vigilant post-market surveillance.

Globally, disparities in access to cancer care highlight the importance of initiatives like the WHO’s Global Strategy for Cancer Control, which aims to improve early detection, vaccination, and access to essential medicines. As these efforts converge, they are poised to create a more equitable and effective oncology landscape worldwide.

Research and Development

The future of oncology treatment is being shaped by ongoing research and development efforts that promise to bring new therapies and treatment strategies to the forefront. Experimental therapies, such as oncolytic viruses, gene therapies, and novel immunotherapies, are currently being tested in clinical trials and hold great potential for improving cancer outcomes. The focus is also shifting towards understanding the tumor microenvironment, which could lead to the development of treatments that disrupt cancer-supporting conditions within the body. As research continues, we can expect to see more targeted and effective treatments that offer better outcomes with fewer side effects.

Regulatory Trends

Regulatory bodies are adapting to the fast-paced advancements in oncology by implementing accelerated approval processes and more flexible regulatory pathways. Initiatives like the FDA’s Breakthrough Therapy designation and the European Medicines Agency’s (EMA) PRIME scheme are designed to expedite the approval of therapies that show significant promise in early clinical trials. These trends are enabling faster access to innovative treatments for patients with life-threatening cancers. However, this also places a greater emphasis on post-market surveillance to ensure the safety and efficacy of these rapidly approved drugs. As the landscape of oncology evolves, regulatory frameworks will need to continuously adapt to balance innovation with patient safety.

Global Perspectives

Oncology treatment trends are not uniform across the globe, with significant variations in how different countries approach cancer care. High-income countries are leading in the adoption of advanced technologies and personalized medicine, while low- and middle-income countries face challenges in accessing even basic cancer treatments. Global health initiatives, such as the World Health Organization’s (WHO) Global Strategy for Cancer Control, aim to address these disparities by promoting early detection, vaccination programs, and access to essential medicines. Collaboration between countries, sharing of best practices, and investment in global health infrastructure are essential for improving cancer care worldwide. The influence of global health policies and initiatives will play a critical role in shaping the future of oncology treatment.

Conclusion

Summary of Key Points

The field of oncology is undergoing a profound transformation, driven by emerging therapies, technological innovations, and a shift towards patient-centered care. From the rise of immunotherapies and targeted treatments to the integration of AI and personalized medicine, these advancements are redefining how cancer is treated. However, challenges such as access, affordability, and ethical considerations remain, highlighting the need for continued innovation and policy reform.

Implications for Patients and Providers

For patients, these trends offer new hope and better outcomes, but they also require greater involvement in treatment decisions and an understanding of the potential risks and benefits. For healthcare providers, staying informed about these trends is crucial to delivering the best possible care and ensuring that patients have access to the latest treatments. Both patients and providers must navigate the complex landscape of oncology with a focus on achieving the best possible outcomes.

Oznur Seyhun, August 2024

10 FAQs related to “Transforming Oncology: Emerging Therapies, Technological Innovations, and Patient-Centered Care”:

1. What are the latest advancements in cancer treatment?
   • The latest advancements include immunotherapy, targeted therapy, personalized medicine, and the integration of artificial intelligence in diagnostics and treatment planning.
2. How does immunotherapy work in treating cancer?
   • Immunotherapy works by stimulating the body’s immune system to recognize and attack cancer cells, using methods like checkpoint inhibitors and CAR-T cell therapy.
3. What is the role of personalized medicine in oncology?
   • Personalized medicine tailors cancer treatment based on the genetic makeup of a patient’s tumor, allowing for more targeted and effective therapies.
4. What are targeted therapies, and how do they differ from traditional chemotherapy?
   • Targeted therapies specifically attack cancer cells by interfering with molecules involved in tumor growth, unlike chemotherapy, which can affect both cancerous and healthy cells.
5. How is artificial intelligence being used in cancer treatment?
   • AI is used in cancer treatment for early diagnosis, predicting treatment outcomes, personalizing treatment plans, and accelerating drug discovery.
6. What challenges are associated with access to advanced cancer treatments?
   • Challenges include geographic, socioeconomic, and systemic barriers that limit access, particularly in low-income regions, and the high costs of new therapies.
7. What are combination therapies, and why are they important in cancer treatment?
   • Combination therapies involve using multiple treatment modalities, such as immunotherapy with chemotherapy, to improve efficacy and reduce resistance in cancer treatment.
8. How do advancements in genomics influence cancer treatment?
   • Genomic advancements allow for detailed profiling of tumors, leading to more precise treatment options and the development of therapies targeting specific genetic mutations.
9. What ethical issues are emerging with the rapid pace of innovation in oncology?
   • Ethical issues include concerns about genetic data privacy, informed consent, and equitable access to new, potentially life-saving treatments.
10. How are global health initiatives addressing disparities in cancer care?
    • Global health initiatives aim to improve access to essential cancer treatments, promote early detection, and ensure equitable healthcare delivery across different regions.

References

• Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. https://doi.org/10.1016/j.addr.2012.09.037
• Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197-198. https://doi.org/10.1001/jama.2017.7156
• Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clinical Cancer Research, 21(4), 687-692. https://doi.org/10.1158/1078-0432.CCR-14-1860
• Chow, R. D., Chen, S., & Wang, G. (2021). CRISPR/Cas9 for cancer therapy: Prospects and challenges. Cancer Research, 81(17), 4292-4300. https://doi.org/10.1158/0008-5472.CAN-21-0133
• Cohen, M. H., Cortazar, P., Justice, R., & Pazdur, R. (2015). Approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-line therapy and beyond. The Oncologist, 20(12), 1425-1431. https://doi.org/10.1634/theoncologist.2015-0277
• Dang, C. V. (2012). MYC on the path to cancer. Cell, 149(1), 22-35. https://doi.org/10.1016/j.cell.2012.03.003
• Dhanasekaran, R., Baylot, V., & Le Meur, N. (2015). Targeting angiogenesis in cancer: Updates and perspectives. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 1856(1), 130-145. https://doi.org/10.1016/j.bbcan.2015.05.004
• Eggermont, A. M. M., & Robert, C. (2015). New drugs in oncology: Innovation, clinical benefit, and price. The Oncologist, 20(4), 419-421. https://doi.org/10.1634/theoncologist.2015-0106
• Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015). Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 15(12), 747-756. https://doi.org/10.1038/nrc4015
• Le Deley, M. C., Leblond, P., Desandes, E., Shamsaldin, A., Rubino, C., & Sommelet, D. (2004). Risk factors for second malignant neoplasms after childhood cancer: Exposure to irradiation and alkylating agents. Nature Reviews Cancer, 4(10), 759-767. https://doi.org/10.1038/nrc1458
• Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2018). Immune checkpoint inhibitors: Expanding roles in cancer therapy. Mayo Clinic Proceedings, 93(1), 68-85. https://doi.org/10.1016/j.mayocp.2017.11.005
• Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61. https://doi.org/10.1126/science.aaa8172
• Subbiah, V., & Kurzrock, R. (2018). The emerging role of liquid biopsy in precision oncology. Nature Reviews Clinical Oncology, 15(5), 318-331. https://doi.org/10.1038/nrclinonc.2018.4
• Wouters, H., Houtepen, R., & Denig, P. (2013). Personalized medicine: Understanding the importance of individual patient characteristics in the treatment of cancer. Journal of Clinical Oncology, 31(10), 1313-1321. https://doi.org/10.1200/JCO.2012.43.2842
• Zhang, W., & Ota, T. (2019). Artificial intelligence in early-stage cancer detection and diagnosis. Nature Biomedical Engineering, 3(6), 423-431. https://doi.org/10.1038/s41551-019-0397-2

Oznur Seyhun